Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00794820 · ClinicalTrials.gov registry record · Phase 2
Fludarabine, Cyclophosphamide, and Rituximab - High Dose Frontline
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
NCT00794820: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00794820 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 66 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00794820, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
Study Summary
Primary Objective: * To evaluate the efficacy (combined morphologic and flow remissions) of a combination of fludarabine, cyclophosphamide and multiple dose rituximab as frontline therapy for CLL. Secondary Objective: * To evaluate remission duration and survival.
Interventions
- DRUG Cyclophosphamide
- DRUG Rituximab
- DRUG Fludarabine Phosphate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2003-12 |
| Est. Completion | 2014-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00794820
The ClinicalTrials.gov registry entry for NCT00794820 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT00794820 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00794820 about?
NCT00794820 is a clinical study titled "Fludarabine, Cyclophosphamide, and Rituximab - High Dose Frontline". Primary Objective: * To evaluate the efficacy (combined morphologic and flow remissions) of a combination of fludarabine, cyclophosphamide and multiple dose rituximab as frontline therapy for CLL. Secondary Objective: * To evaluate remission duration and survival.
What is the current status of trial NCT00794820?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2003-12. Estimated completion is 2014-12.
What interventions are being tested in trial NCT00794820?
The interventions under investigation include: Cyclophosphamide (DRUG), Rituximab (DRUG), Fludarabine Phosphate (DRUG).
Who is sponsoring clinical trial NCT00794820?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.